A Randomized Phase 2 Study of AMG 386 With or Without Continued Anti-vascular Endothelial Growth Factor (VEGF) Therapy in Patients With Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib

Trial Profile

A Randomized Phase 2 Study of AMG 386 With or Without Continued Anti-vascular Endothelial Growth Factor (VEGF) Therapy in Patients With Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Trebananib (Primary) ; Bevacizumab; Pazopanib; Sorafenib; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Apr 2017 Planned primary completion date changed to 1 Dec 2017.
    • 10 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Dec 2016.
    • 07 Jun 2016 Interim results (n=35) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top